Exac Trac® SABR Knife
California Pacific Medical Center offers state-of-the-art treatment modalities and now includes the technological advances of the Exac Trac® Stereotactic Ablative Brain Radiation (SABR) Knife. We are now able to treat brain, prostate, lung, spine or pancreas cancers using the fastest stereotactic radiosurgery (SRS) treatments available. With the ExacTrac® SABR Knife frameless radiosurgery treatments, using automatic setup and Trilogy’s delivery system, most patients are in and out of the treatment room within 15 to 25 minutes and in one to five treatment sessions.
Precision Technology and Advanced Care
In addition to the tumors listed above, ExacTrac SABR Knife therapy is also available to treat your patients with AVM, trigeminal neuralgia, and acoustic neuroma. SABR Knife is a linear accelerator based non-invasive alternative to surgery for the treatment of both malignant and benign tumors anywhere in the body. Using real-time tracking and robotic couch, SABR Knife’s capabilities include Intensity Modulated Radiosurgery (IMRS), the next evolution to IMRT. SABR Knife’s image-guided radiation therapy (IGRT) system provides greater accuracy in targeting tumors, allowing us to treat a greater range of conditions.
SABR Knife technology uses high-resolution X-rays to identify tumors seconds before treatment, automatically correcting patient positioning due to any tumor or patient movements. With this technology, we can deliver more precise, higher treatment doses with submillimeter accuracy, significantly reducing the risk of radiation exposure to surrounding healthy tissue.
Providing More Treatment Options
Brain: Patients with trigeminal neuralgias, AVMs and acoustic neuromas can now be treated at California Pacific. SABRKnife will allow treatment of these diagnoses with submillimeter precision
Prostate: Patients with early or intermediate stage prostate cancer will have the option of the SABRKnife using fiducial markers. Patients will be able to complete their treatments in five treatments as compared to the standard 8-9 weeks of external beam treatment. Recent published studies demonstrate equivalent outcomes as compared to external beam radiotherapy.
Lung: Patients with early stage (T1 or T2) lung cancers have the option of receiving 3-5 outpatient treatments as an alternative to surgery in the case of inoperable tumors or patients that are poor surgical candidates.
Spine: Some patients with spinal tumors are surgically complex or inoperable. Spinal primary tumors such as meningiomas, neurofibromas, schwannomas, astrocytomas and ependymomas or metastatic from other sites will now have this new non-surgical treatment option.
Pancreas: Patients with pancreatic cancers that are inoperable will have this new SABRknife treatment option available.